A 51-year-old woman with HIV is seen in the clinic and reports recent close contact with an individual who had recently been diagnosed with active tuberculosis. This information has been verified with the local health department. She is asymptomatic. An interferon gamma release assay (IGRA) is negative, and the chest radiograph is normal. The most recent laboratory studies obtained 2 months prior showed a CD4 count of 412 cells/mm3 and an undetectable HIV RNA level. She has been taking dolutegravir-lamivudine for about 18 months.
Which of the following describes the next best step in management?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
January 29th, 2025
January 29th, 2025
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant